Illumina wins case against FTC on grail acquisitions

An administrative law judge has agreed Illumina in its $7.1 billion acquisition of cancer-testing developer Grail Inc., dealing a defeat to the Federal Trade Commission’s attempt to scuttle the deal on antitrust grounds, the company said.

Illumina said the judge rejected the FTC’s position that the deal would harm competition in the market for early-detection tests for multiple cancers.

Source link

Back to top button